Why the study?
Angiotensin II induces renal fibrosis and inflammation related to hypertension, and the study aimed to determine the effect of the cholinergic anti-inflammatory pathway on renal inflammation and fibrosis.
Does activation of the cholinergic anti-inflammatory pathway with GTS-21 reduce Angiotensin II-induced hypertension and renal fibrosis in a rat model?
Does activation of the cholinergic anti-inflammatory pathway with GTS-21 reduce Angiotensin II-induced hypertension and renal fibrosis in a rat model?
Activation of the cholinergic anti-inflammatory pathway with GTS-21 attenuates Angiotensin II-induced hypertension and renal fibrosis in rats, suggesting a potential therapeutic target for hypertension-related renal injury.
CAP mitigates AngII-induced renal inflammation and fibrosis in preclinical models; leaves open whether vagal stimulation benefits human hypertensive nephropathy.
Background : Angiotensin II (AngII) induces renal fibrosis, characterized by fibroblast proliferation, inflammatory cell infiltration and excessive extracellular matrix deposition, all of which was relevant closely to hypertension. The vagus nerve-related cholinergic anti-inflammatory pathway (CAP) modulates local and systemic inflammatory responses. The aim of present study was to determine the effect of CAP on renal inflammation and fibrosis. Methods and Results : AngII-induced hypertension was induced in vivo by 14-days low-dose AngII infusion from osmotic minipumps. We used GTS-21 dihydrochloride, a selective nicotinic acetylcholine receptor agonist. Daily intraperitoneal GTS-21 injection and/or vagotomy started after hypertension was confirmed and continued for 4 weeks. The elevated blood pressure caused by AngII was significantly attenuated by GTS-21. Improved baroreflex sensitivity was observed after GTS-21 administration. Masson stain and immunoblotting revealed that deposition of excessive fibrosis and overexpression of inflammatory cytokines induced by AngII was reduced by GTS-21. To determine the role of autonomic control in CAP, unilateral vagotomy was performed. Vagotomy weakened the effect of CAP on AngII-induced hypertension. In vitro , GTS-21 suppressed NF-κB activation, attenuated AngII-induced epithelial-mesenchymal transition and reduced inflammation and fibrosis in NRK-52E cells; α-bungarotoxin (α-Bgt, an α7-nAChR selective antagonist) partly inhibited these effects. Conclusion: CAP protected against AngII-induced hypertension via improvement in autonomic control, suppression of NF-κB activation, and reduction of renal fibrosis and inflammatory response.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: